Molecular profile of IMFT for the identification of potential druggable targets and biomarkers predicting crizotinib response.

ABSTRACT: The clinical phase II trial EORTC 90101 “CREATE†showed high anti-tumor activity of crizotinib, an ALK/ROS1 inhibitor, in IMFT patients. However, results suggested that other molecular targets in addition to ALK/ROS1 might also contribute to the sensitivity of this kinase inhibitor. We therefore characterized molecular profile of IMFT to identify alterations which could play a role in the response to crizotinib.

PROVIDER: EGAS00001005419 | EGA |

REPOSITORIES: EGA